1Sossalla S, Maier LS. Role of ranolazine in angina,heart fail- ure, arrhythmias, and diabetes[J]. Pharmacol Ther, 2012, 133 (3) 311.
2Charles A, Luiz B, Andrew CZ, et al. Electrophysiologic effects of ranolazine, a novel anti-angiNaL agent with antiar- rhythmic properties[J]. Circulation, 2004, 110(8) : 904.
3Alexander B, Jose MD, Luiz B, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation differences in sodium channel inactivation between atria and ventricles and the role of ranolazine[J]. Circulation, 2007, 116 (13):1 449.
4Pezhouman A, Madahian S,Stepanyan H, et al. Selective inhi- bition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts[J], Heart Rhythm, 2014,11 (3) :492.
5Samure S, Nora W, Karl T, et ah Effects of ranolazine on tor- sades de pointes tachycardias in a healthy isolated rabbit heart model[J]. Cardiovase Ther,2014, 32(4) : 170.
6Arthur B, Peter RS, Santiago R, et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel NaV1.5 a novel mechanism of drug action [J]. Circulation, 2012,125(22) :2 698.
7Yogananda SM, Courtnetr RR, Luis B, et al. Ranolazine blocks the enhanced late Na+ current and shortens the action potential duration in ventrieular myocytes from lamin A/C mu- tant (LmnaN195K) mice [J]. Circulation, 2013, 128(22): A150.
8Huang H, Silvia GP, Carlo N, et al. Y1767C,a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Navl. 5 channels, [J]. J Physiol Heart Circ Physiol, 2011, 300(1),2S8.
9Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interac- tions of ranolazine with HERG K+ current [J]. Cardiovasc Pharmacol, 2008, 51(66) ..581.
10Johannesen L, Vicente J, Mason JW, et al. Differentiating drug- induced multichannel block on the electrocardiogram: random- ized study of dofetilide, quinidine, ranolazine, and verapamil [J]. CliniCal Trial,2014,96(5) ..549.
